Fig. 1From: Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trialMeasurements and investigations. Legend section: SF-36 Short Form (36) Health Survey, CLDQ Chronic Liver Disease Questionnaire, AE adverse event, *by transient and shear wave elastography, **by weight and hand grip strengthBack to article page